Free Shipping On Orders Over $1,000!

Bcl2 (Ser87) Polyclonal Antibody, FITC Conjugated

Applications

  • FCM
  • IF(IHC-P)
  • IF(IHC-F)
  • IF(ICC)

Reactivity

  • Human
  • Rat

Predicted Reactivity

  • Mouse
  • Horse
  • Rabbit
Overview
Catalog # bs-12577R-FITC
Product Name Bcl2 (Ser87) Polyclonal Antibody, FITC Conjugated
Applications FCM, IF(IHC-P), IF(IHC-F), IF(ICC)
Reactivity Human, Rat
Predicted Reactivity Mouse, Horse, Rabbit
Specifications
Conjugation FITC
Host Rabbit
Source KLH conjugated synthetic phosphopeptide derived from human Bcl2 around the phosphorylation site of Ser87
Modification Site Ser87
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Gene ID 596
Subcellular location Cytoplasm, Nucleus, Cell membrane
Synonyms Bcl2 phospho S87; Bcl2 phospho Ser87; p-Bcl2 phospho S87; p-Bcl2 Ser87; Apoptosis regulator Bcl 2; Apoptosis regulator Bcl2; AW986256; B cell CLL/lymphoma 2; B cell leukemia/lymphoma 2; B cell lymphoma 2; Bcl 2; Bcl-2; Bcl2; BCL2 protein; C430015F12Rik; D630044D05Rik; D830018M01Rik; Leukemia/lymphoma, B-cell, 2; Oncogene B-cell leukemia 2; BCL2_HUMAN; Apoptosis regulator Bcl-2.
Background BCL2 is an integral outer mitochondrial membrane protein that blocks the apoptotic death of some cells such as lymphocytes. Constitutive expression of BCL2, such as in the case of translocation of BCL2 to Ig heavy chain locus, is thought to be the cause of follicular lymphoma. Two transcript variants (alpha and beta) produced by alternate splicing, differ in their C-terminal ends. BCL2 suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. It regulates cell death by controlling the mitochondrial membrane permeability. It appears to function in a feedback loop system with caspases. BCL2 inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF1). It can form homodimers, and heterodimers with BAX, BAD, BAK and BclX(L). Heterodimerization with BAX requires intact BH1 and BH2 domains, and is necessary for anti-apoptotic activity. Also interacts with APAF1, RAF1, TP53BP2, BBC3, BCL2L1 and BNIPL.
Application Dilution
FCM 1:20-100
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200